SCYNEXIS reports Q3 net loss $0.6M; BREXAFEMME net sales $0.5M in first partial quarter

SCYNEXIS INC

2021-Q3 EPS reported -$0.73 revenue$12,566,000

BREXAFEMME net sales $0.5M in partial Q3; IQVIA 1,006 prescriptions in Q3, 1,100 in October.
R&D expense $4.4M (-45% YoY); SG&A $15.4M (+341% YoY driven by commercial launch costs).
Net loss $0.6M ($0.02 per basic share) vs net income $0.9M in Q3 2020.
Cash $100.1M; runway projected into 2023.
CFO Eric Francois resigning; Danforth Advisors providing interim CFO Lawrence Hoffman.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.